Slide 1: Welcome to the 3Q23 webinar
Welcome to the 3Q23 webinar 20th October 2023
Slide 2: This is Modulight
This is Modulight We fight cancer with science and technology ▪ We are a biomedical company ▪ We also manufacture products that designs and manufactures for other high-value applications laser devices for the treatment such as flow cytometry, quantum of cancer and eye diseases and computing and digi
Slide 3: Today's agenda
Today’s agenda ▪ Q3 in brief ▪ US launch update ▪ Our technology ▪ Financial highlights ▪ R&D pipeline ▪ Customer base and events ▪ Revenue model ▪ Outlook ▪ Summary ▪ Q&A 3
Slide 4: Q3 in brief
Q3 in brief ▪ Focused especially on ▪ projects based on the SaaS business model and related customer audits ▪ improving our productivity ▪ Revenue EUR 406 thousand (delays PPT & projects) We will focus on ▪ EBITDA EUR -2,210 thousand implementing actions in line with our growth ▪ R&D pipeline remain
Slide 5: U.S. launch update
U.S. launch update Lorem ipsum ▪ In January, pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA) for our laser device for the treatment of wet age-related macular degeneration (AMD) ▪ Customer visits continued ▪ Hired a Sales Director responsible for the North American market,
Slide 6: Unique technology
Unique technology ▪ Projects with experts in the field show confidence in our unique technology ▪ Example: a customer who has used our technology since 2014 ▪ Project has now progressed to Phase 3 clinical trials with a large population ▪ P3 is purely based on our technology ▪ The customer has since
Slide 7: Benefits of our technology confirmed in a study
Benefits of our technology confirmed in a study ▪ In September, the prestigious Science ▪ Life cycle management investments in Advances journal published a study on pharmaceutical industry are typically our technology used in treatment of considered to have lower risk, higher ovarian cancer. Same ar
Slide 8: Financial highlights July–September 2023
Financial highlights July–September 2023 ▪ Revenue -67% YoY due to delays in some projects ▪ Costs increased due to Revenue EBITDA EBIT investments in developing our operations ▪ Increased number of EUR EUR EUR personnel 406 -2,537 -3,074 ▪ New production equipment thousand thousand thousand ▪ Share
Slide 9: Financial highlights January–September 2023
Financial highlights January–September 2023 ▪ Revenue -9,8% YoY due to delays in projects in commercialization phase Revenue EBITDA EBIT ▪ Costs increased due to investments in developing our operations ▪ Increased number of EUR EUR EUR personnel 3,006 -5,547 -7,072 ▪ New production equipment thousa
Slide 10: Key figures
Key figures Group EUR 1,000 unless otherwise noted 7–9/2023 7–9/2022 1–9/2023 1–9/2022 1–12/2022 1) Revenue 406 1,232 3,006 3,331 4,599 EBITDA -2,537 -1,342 -5,547 -3,936 -5,936 EBITDA - % -624.8% -108.9% -184.5% -118.2% -129.1% Operating result (EBIT) -3,074 -1,812 -7,072 -5,292 -7,792 Operating re
Slide 11: Solid R&D pipeline
Solid R&D pipeline ▪ 27 projects Number of projects with commercialization potential ▪ All projects progressed 30 ▪ Several projects are close to the commercialization phase, 25 and we estimate their revenue potential to be 20 significant next year 15 ▪ One new patent application filed 10 ▪ A few ne
Slide 12: Modulight's customer base
Modulight’s customer base Customer ownership 30 ▪ 11% are research companies 25 ▪ 30% are privately owned 20 ▪ 59% of customers are 15 listed companies 10 ▪ 63% are established companies 5 ▪ 30% have over 1bn revenue 0 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 Hospitals and research institutions
Slide 13: International Photodynamic Association's World Congress
International Photodynamic Association’s World Congress ▪ In July, Modulight organized and hosted the World Congress of the International Photodynamic Association in Tampere, Finland ▪ 250 participants from 29 countries with many being the most senior scientists and thought leaders in the field – wi
Slide 14: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts share of pharmaceutical or treatment principle, without revenue risk for Modulight fees, or the utilization rate of industrial applications. Predictability of Modulight’s revenue is improving Curre
Slide 15: Pay Per Treatment update
Pay Per Treatment update ▪ We promote transition to pay per treatment pricing ▪ Based on our analysis and discussions with many customers, we estimate that the price per treatment session is around 1,000€ – 10,000€ ▪ This price range typically represents 1–10% of the total cancer treatment costs In
Slide 16: US healthcare market economics
US healthcare market economics ▪ To support the implementation of pay-per-treatment business models, we have studied & analysed the costs related to current standard of care in the US with KPMG for 11 indications in oncology and ophthalmology – work continues but we can now share some interim result
Slide 17: Outlook
Outlook Modulight has not issued guidance for revenue or profitability in 2023. As the company’s customer projects are still distributed across varying early stages of development, and predicting developments in the market remains challenging, it is difficult to forecast performance in 2023. However
Slide 18: Summary
Summary ▪ Focused especially on projects based on the SaaS business model and related customer audits, as well as improving our productivity ▪ 3Q23 Revenue 406 thousand due to delay in projects & PPT model implementation and EBITDA - 2,210 impacted by our investments in developing and growing our op
Slide 19: Thank you! Questions?
Thank you! Questions? modulight
Slide 20: Thank you
Thank you Please follow us in social media